Quest Diagnostics stock trades near 52-week high after strong earnings momentum

Published on 09/20/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock closed at USD 246.45 on the NYSE on September 18, 2026, just below its 52-week high of USD 248.70. The shares are up about 42.2 percent year to date, supported by double-digit revenue growth and improving margins.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics Incorporated stock (ISIN US74834L1008) closed at USD 246.45 on the New York Stock Exchange on September 18, 2026, leaving the diagnostics specialist trading close to its 52-week high of USD 248.70 and reflecting ongoing optimism about its earnings momentum and outlook, as highlighted in a recent overview from Ad-hoc-news on September 19, 2026.

Stock performance and trading metrics

According to price data summarized by Ad-hoc-news, Quest Diagnostics shares finished the September 18, 2026 session at USD 246.45 on the NYSE, down 0.40% from the prior close of USD 247.45, with an intraday range between USD 244.89 and USD 247.62 and trading volume of about 1,924,740 shares, roughly double the average daily volume of 977,487 shares.

The same overview notes that Quest Diagnostics has traded in a 52-week range between USD 171.18 and USD 248.70, so the September 18, 2026 closing price of USD 246.45 places the stock just USD 2.25, or around 0.9%, below its 52-week high, underscoring how firmly the shares are positioned near the top of their recent trading band as investors digest recent results and guidance, based on figures referenced by Ad-hoc-news on September 19, 2026.

Year-to-date gains and analyst context

For investors, the longer-term price move is equally striking: MarketBeat data cited by Ad-hoc-news indicate that Quest Diagnostics shares were trading at about USD 173.47 at the beginning of 2026 and have risen by approximately 42.2% to around USD 246.65 by September 18, 2026, far outpacing the broader S&P 500 index over the same period.

As the same article reports, Yahoo Finance data show a year-to-date total return of 43.88% for Quest Diagnostics as of September 18, 2026, compared with 11.76% for the S&P 500, meaning the stock has delivered more than triple the benchmark’s gain so far this year and highlighting that the market has rewarded the company’s ability to grow revenue and improve profitability, according to Ad-hoc-news.

Fundamentals and margin development

The recent price strength is underpinned by improving fundamentals. While the latest detailed quarterly figures are not fully laid out in the recent market snapshot, the same coverage attributes the stock’s advance to double-digit revenue growth and better margins in the most recently reported periods, with investors also responding positively to ongoing dividend payments and share buybacks, according to the analysis from Ad-hoc-news on September 19, 2026.

In addition, consensus data referenced in a peer comparison of large US diagnostics companies suggest that analyst expectations for Quest Diagnostics remain constructive but not euphoric: in a discussion of sector leaders, MarketBeat’s overview cited by Ad-hoc-news notes that Quest Diagnostics carries a consensus price target of USD 236.31, implying a potential downside of about 4.19% from its closing level around USD 246.65 on September 18, 2026.

Sector comparison and risk considerations

The comparison with rival Labcorp Holdings underlines that, within the US diagnostics sector, some analysts currently see relatively more upside elsewhere: the same peer review indicates that Labcorp has a higher implied upside to its consensus price target than Quest Diagnostics, a contrast that suggests the latter’s strong year-to-date performance may have already priced in much of the near-term earnings momentum, as outlined by Ad-hoc-news on September 20, 2026.

For shareholders, the key risk highlighted by this valuation setup is that the stock’s current level, just below its 52-week high and above the average analyst target, leaves limited room for disappointment: any slowdown in revenue growth, pressure on margins or shift in reimbursement patterns could translate into a period of consolidation or pullback from the present price corridor, a scenario implied by the modest downside to consensus described in the MarketBeat and Yahoo Finance data quoted by Ad-hoc-news.

Quest Diagnostics stock near recent highs

With Quest Diagnostics stock closing at USD 246.45 on the NYSE on September 18, 2026, the shares currently trade just below the 52-week high of USD 248.70 and around 42% above their level at the start of the year, while the company’s market capitalization stands at about USD 27.20 billion as of September 18, 2026, illustrating how strongly the market now values the diagnostics group’s earnings power and growth prospects based on the figures reported by Ad-hoc-news.